AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00655876
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
Trial: NCT01831765
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
Trial: NCT01831765
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
Trial: NCT01831765
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted.
Trial: NCT01831765
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
Trial: NCT03582033
Drug: SEA-BCMA
RxNorm normalized name: SEA-BCMA
DrugBank: SEA-BCMA (DB18309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously)
Trial: NCT02322463
Drug: Arab children
RxNorm normalized name: Arabic gum
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Oxycodone
Trial: NCT00202423
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006055
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006055
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006055
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006055
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006055
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04269538
Drug: PF-06480605
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605 150 mg and 450 mg SC dosing
Trial: NCT03582033
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by mouth (orally) or by IV
Trial: NCT03582033
Drug: pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03967496
Drug: Preoperative Medication
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative medications
Trial: NCT02393443
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
Trial: NCT02118090
Drug: Chloroquine sulfate
RxNorm normalized name: Chloroquine sulfate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
Trial: NCT04120090
Drug: low dose ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
Trial: NCT04120090
Drug: high dose ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
Trial: NCT00787059
Drug: Sucrose (3%)
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00556400
Drug: Lo-Ovral Oral Contraceptive Pills
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00457899
Drug: Quetiapine IR (Immediate Release)
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04173832
Drug: Tianqi Pingchan Granule Combined With Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
Trial: NCT04173832
Drug: Placebo Combined With Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo and Amantadine are given to patients simultaneously
Trial: NCT00441506
Drug: daily interruption of sedatives
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00077545
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00077545
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00468260
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00654966
Drug: Soluble epoxide hydrolase
RxNorm normalized name: SOLUBLE EPOXIDE HYDROLASE
DrugBank: Bifunctional epoxide hydrolase 2 (DB15139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Trial: NCT00196625
Drug: Amprenavir (drug)
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00196625
Drug: Ritonavir (drug)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00654758
Drug: M200 (Volociximab), Carboplatin, Paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
Trial: NCT00593736
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
Trial: NCT00593736
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
Trial: NCT00593736
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
Trial: NCT01868893
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01868893
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00967291
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,500 mg/mq on days 1-3 every 28 days
Trial: NCT00967291
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/mq on day 1 every 28 days
Trial: NCT03825341
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
Trial: NCT00459121
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
Trial: NCT00459121
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
Trial: NCT00459121
Drug: Zactima
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
Trial: NCT00002608
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002608
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04283500
Drug: Buprenorphine Naloxone
RxNorm normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
Trial: NCT00989027
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Trial: NCT00989027
Drug: Ergonovine
RxNorm normalized name: Ergonovine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Trial: NCT00989027
Drug: Carboprost
RxNorm normalized name: Carboprost
DrugBank: Carboprost (DB19356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Trial: NCT00989027
Drug: Oxytocin and Ergonovine
RxNorm normalized name: ergonovine / oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Trial: NCT00989027
Drug: Oxytocin and Carboprost
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Trial: NCT01067235
Drug: BF2.649 add on Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
Trial: NCT01149967
Drug: Citalopram Hydrobromide
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
Trial: NCT01725620
Drug: LBEC0101 (Etanercept 25mg)
RxNorm normalized name: etanercept 25 MG/ML
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00045188
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02595749
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02832999
Drug: sub cutaneous liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 1.2mg/day
Trial: NCT02832999
Drug: Oral Vildagliptin
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 50mg/day
Trial: NCT01725620
Drug: Enbrel (Etanercept 25mg)
RxNorm normalized name: etanercept 25 MG/ML [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00106392
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00144664
Drug: MRA(Tocilizumab)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00423475
Drug: goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217787
Drug: PF-06372865
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg as 3 x 2.5 mg tablets single dose
Trial: NCT00002883
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00416650
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive 150 mg orally daily
Trial: NCT00405886
Drug: Neramexane
RxNorm normalized name: Neramexane
DrugBank: Neramexane (DB04926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, duration: 16 weeks
Trial: NCT00742924
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00742924
Drug: dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00742924
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00742924
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00742924
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02452983
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00195637
Drug: Immune Globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02196701
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection every other week.
Trial: NCT00406744
Drug: Intravitreal injection of Bevacizumab
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01930955
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-lactam antibiotics
Trial: NCT00643565
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
Trial: NCT01877226
Drug: Tapentadol
RxNorm normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
Trial: NCT00783016
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01283594
Drug: Tozadenant (SYN115) 60 mg BID
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID.
Trial: NCT01283594
Drug: Tozadenant (SYN115) 120 mg BID
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID.
Trial: NCT01283594
Drug: Tozadenant (SYN115) 180 mg BID
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID.
Trial: NCT01283594
Drug: Tozadenant (SYN115) 240 mg BID
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID.
Trial: NCT04373044
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04373044
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03856112
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03856112
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03856112
Drug: Ixazomib Citrate
RxNorm normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03856112
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02072044
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib p.o. qd
Trial: NCT01177410
Drug: Mesalamine Granules 750 mg
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 750 mg mesalamine granules once daily for 12 weeks
Trial: NCT01177410
Drug: Mesalamine Granules 1500 mg
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg mesalamine granules once daily for 12 weeks
Trial: NCT02640053
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00242736
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01688570
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
Trial: NCT01688570
Drug: Cyproheptadine
RxNorm normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
Trial: NCT02365558
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02365558
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00369317
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00369317
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00369317
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT00369317
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00369317
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03809988
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
Trial: NCT01592305
Drug: atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: multiple oral doses